The Convergence Frontier: Integrating Machine Learning and High Performance Quantum Computing for Next-Generation Drug Discovery

TL;DR

This paper discusses how integrating HPC, ML, and QC can revolutionize drug discovery by enabling quantum-accurate simulations at scale, overcoming classical computational limitations.

Contribution

It introduces the concept of High-Performance Quantum Computing with hybrid architectures as a key enabler for next-generation quantum chemistry simulations in drug discovery.

Findings

ML foundation models enable quantum-accurate simulations

Hybrid QPU-GPU architectures accelerate quantum chemistry data generation

Quantum-enhanced sampling advances modeling of reactive cellular systems

Abstract

Integrating quantum mechanics into drug discovery marks a decisive shift from empirical trial-and-error toward quantitative precision. However, the prohibitive cost of ab initio molecular dynamics has historically forced a compromise between chemical accuracy and computational scalability. This paper identifies the convergence of High-Performance Computing (HPC), Machine Learning (ML), and Quantum Computing (QC) as the definitive solution to this bottleneck. While ML foundation models, such as FeNNix-Bio1, enable quantum-accurate simulations, they remain tethered to the inherent limits of classical data generation. We detail how High-Performance Quantum Computing (HPQC), utilizing hybrid QPU-GPU architectures, will serve as the ultimate accelerator for quantum chemistry data. By leveraging Hilbert space mapping, these systems can achieve true chemical accuracy while bypassing the heuristics of classical approximations. We show how this tripartite convergence optimizes the drug discovery pipeline, spanning from initial system preparation to ML-driven, high-fidelity simulations. Finally, we position quantum-enhanced sampling as the beyond GPU frontier for modeling reactive cellular systems and pioneering next-generation materials.